An Open-Label Expanded Access Protocol for Apalutamide Treatment of Subjects With Non Metastatic Castration-Resistant Prostate Cancer
Phase of Trial: Phase III
Latest Information Update: 20 Nov 2019
Price : $35 *
At a glance
- Drugs Apalutamide (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Expanded access
- Sponsors Johnson & Johnson
- 26 Jul 2018 Status changed from not yet recruiting to recruiting.
- 30 May 2018 Planned initiation date changed from 4 May 2018 to 11 Jul 2018.
- 30 May 2018 Planned End Date changed from 10 Jun 2021 to 26 Jul 2021.